Literature DB >> 6744284

The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

J H Goldie, A J Coldman.   

Abstract

Drug resistance continues to be a major factor in limiting the effectiveness of cancer chemotherapy. Evidence from a variety of sources implicates a genetic basis for most drug-resistant phenotypes. Assuming a random spontaneous origin for these resistant cells, it is possible to develop mathematical and computer-based models of the drug treatment of tumors. These can provide a more intuitive understanding of the basis of treatment success or failure. This in turn may lead to the development of more rational and effective treatment protocols. Studies of phenomena such as pleiotropic drug resistance are providing insights into how multiple levels of drug resistance occur and are yielding information on how certain types of drug resistance may be prevented or overcome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744284

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  96 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Authors:  Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 4.  Mutation and epigenetic molecular clocks in cancer.

Authors:  Darryl Shibata
Journal:  Carcinogenesis       Date:  2010-11-12       Impact factor: 4.944

Review 5.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

6.  Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.

Authors:  Hisataka Kitano; Yoh Masaoka; Atsushi Mamiya; Yusuke Fujiwara; Toshio Miki; Chiaki Hidai
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 7.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

8.  Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.

Authors:  Manuel Cobo Dols; Esther Villar Chamorro; Inmaculada Alés Díaz; Silvia Gil Calle; Julia Alcalde García; Vanesa Gutiérrez Calderón; Francisco Carabantes Ocón; Alvaro Montesa Pino; Juan J Bretón García; Manuel Benavides Orgaz
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

9.  Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.

Authors:  Amanda Jane Williams Gibson; Haocheng Li; Adrijana D'Silva; Roxana A Tudor; Anifat A Elegbede; Shannon Mary Otsuka; D Gwyn Bebb; Winson Y Cheung
Journal:  Med Oncol       Date:  2018-08-02       Impact factor: 3.064

Review 10.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.